KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025)

Regeneron Pharmaceuticals has reported Operating Leases over the past 4 years, most recently at $986.8 million for Q4 2025.

  • Quarterly results put Operating Leases at $986.8 million for Q4 2025, up 3.39% from a year ago — trailing twelve months through Dec 2025 was $986.8 million (up 3.39% YoY), and the annual figure for FY2025 was $986.8 million, up 3.39%.
  • Operating Leases for Q4 2025 was $986.8 million at Regeneron Pharmaceuticals, up from $954.4 million in the prior quarter.
  • Over the last five years, Operating Leases for REGN hit a ceiling of $986.8 million in Q4 2025 and a floor of $788.2 million in Q4 2022.
  • Median Operating Leases over the past 4 years was $881.0 million (2023), compared with a mean of $884.3 million.
  • Biggest five-year swings in Operating Leases: rose 2.47% in 2023 and later rose 18.16% in 2024.
  • Regeneron Pharmaceuticals' Operating Leases stood at $788.2 million in 2022, then rose by 2.47% to $807.7 million in 2023, then rose by 18.16% to $954.4 million in 2024, then grew by 3.39% to $986.8 million in 2025.
  • The last three reported values for Operating Leases were $986.8 million (Q4 2025), $954.4 million (Q4 2024), and $807.7 million (Q4 2023) per Business Quant data.